ClinicalTrials.gg
CompletedNCT02114164Updated Nov 26, 2021Results posted

Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies

An interventional study of AirSeal System and Standard Endopath in Prostate Cancer and Pneumoperitoneum, sponsored by OhioHealth. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-26.

Sponsored by OhioHealth · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
867th of 3,024
109 · median 48
Started
2016
with 136 others
No phase
764 of 3,597
157 open now
Registered
1,560th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 867th largest by enrollment of the 3,024 interventional ones that give a count, is one of 137 that started in 2016, is one of 764 with no phase, and was the 1,560th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.

Read the detailed description

The primary observation to be made is the level of carbon dioxide in the arterial blood, specifically when the patient is insufflated and deflated during the surgery. As a result of the consistent pressure that the AirSeal® system maintains, carbon dioxide will be absorbed in lower levels when compared to the standard of care systems in which fluctuations in intra-peritoneum pressure are seen.

03

Conditions studied

  • Prostate Cancer
  • Pneumoperitoneum

Keywords

  • AirSeal
  • Trocar
  • Carbon Dioxide Exchange and Absorption
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>18
  • Eligible and elect to undergo robotic prostatectomy surgery @ OhioHealth Dublin Methodist Hospital

Exclusion criteria

Exclusion Criteria:

  • Age \< 18
  • Emergency surgery
  • Ascites
  • >44 or \<18
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
109 participants (actual)

Study arms

  • Active comparator
    AirSeal System

    This group receives the AirSeal System for intraoperative insufflation.

    Device: AirSeal System

  • Active comparator
    Standard Endopath

    This group receives the Standard Endopath Trocar for intraoperative insufflation.

    Device: Standard Endopath

Interventions

  • DeviceAirSeal System

    To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.

    Also known as: Valve-free Trocar

  • DeviceStandard Endopath

    This group receives the Standard Endopath Trocar for intraoperative insufflation.

    Also known as: Endopath Trocar

06

What researchers measure

Primary outcomes

  1. Intraoperative Pneumoperitoneal Pressure (mmHg)

    Pneumoperitoneal pressure is the pressure exerted by air or gas in the abdominal (peritoneal) cavity. As the amount of air/gas increases, the pressure (mmHg) increases. The highest pressure that occurred during the procedure was compared between groups.

    Time frame: Through end of procedure, an average of 156 minutes

Secondary outcomes

  1. Intraoperative Arterial Blood Gas Carbon Dioxide (mmHg).

    The amount of dissolved carbon dioxide (PaCO2) in arterial blood (mmHg) during the operative procedure

    Time frame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes

  2. End-tidal Carbon Dioxide Pressure (mmHg)

    End-tidal carbon dioxide pressure is the partial pressure of carbon dioxide at the end of exhalation. Normal value is 35-45 mmHg.

    Time frame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes

  3. Carbon Dioxide Elimination (mmHg)

    Carbon dioxide elimination was calculated using end-tidal carbon dioxide pressure (EtCO2), tidal volume, respiratory rate, barometric pressure (pB = 760mm Hg), partial pressure of water vapor (PH2O = 13 mm Hg), and patient weight (kg)

    Time frame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes

  4. Intraoperative Arterial Blood Gas Oxygen (mmHg).

    The amount of dissolved oxygen (PaO2) in arterial blood (mmHg).

    Time frame: Baseline, 60 minutes, and end of procedure, an average of 156 minutes

  5. Number of Ventilator Interventions

    The number of times the anesthesiologist had to adjust ventilator settings

    Time frame: Through end of procedure, an average of 156 minutes

  6. Procedure Time (Minutes)

    The duration of the procedure

    Time frame: Through end of procedure, an average of 156 minutes

  7. Smoke Evacuation Quality

    Smoke evacuation quality throughout the procedure was assessed by the surgeon as below average, average, or above average

    Time frame: Through end of procedure, an average of 156 minutes

07

Results

Posted Nov 26, 2021

Participant flow

Participant flow — Overall Study
MilestoneAirSeal SystemStandard Endopath
Started5050
Completed5050
Not completed00

Outcome measures

PrimaryIntraoperative Pneumoperitoneal Pressure (mmHg)

Pneumoperitoneal pressure is the pressure exerted by air or gas in the abdominal (peritoneal) cavity. As the amount of air/gas increases, the pressure (mmHg) increases. The highest pressure that occurred during the procedure was compared between groups.

Time frame:
Through end of procedure, an average of 156 minutes
Reported as:
Mean · mmHg
Intraoperative Pneumoperitoneal Pressure (mmHg)
mmHgAirSeal SystemStandard Endopath
Intraoperative Pneumoperitoneal Pressure (mmHg)7.9 ± 2.59.9 ± 2.9
Statistical analysis
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = <0.001
SecondaryIntraoperative Arterial Blood Gas Carbon Dioxide (mmHg).

The amount of dissolved carbon dioxide (PaCO2) in arterial blood (mmHg) during the operative procedure

Time frame:
Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
Reported as:
Mean · mmHg
Intraoperative Arterial Blood Gas Carbon Dioxide (mmHg).
mmHgAirSeal SystemStandard Endopath
Baseline39.5 ± 4.939.2 ± 5.3
60 minutes41.5 ± 7.741.2 ± 5.2
End of procedure45.1 ± 6.144.1 ± 5.5
Statistical analysis
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.39
SecondaryEnd-tidal Carbon Dioxide Pressure (mmHg)

End-tidal carbon dioxide pressure is the partial pressure of carbon dioxide at the end of exhalation. Normal value is 35-45 mmHg.

Time frame:
Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
Reported as:
Mean · mmHg
End-tidal Carbon Dioxide Pressure (mmHg)
mmHgAirSeal SystemStandard Endopath
Baseline31.47 ± 3.929.96 ± 3.1
60 Minutes32.80 ± 3.630.96 ± 3.2
End of procedure34.77 ± 8.934.17 ± 7.2
Statistical analysis
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.13 (Comparison at baseline)
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.018 (Comparison at 60 minutes)
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.712 (Comparison at end of procedure)
SecondaryCarbon Dioxide Elimination (mmHg)

Carbon dioxide elimination was calculated using end-tidal carbon dioxide pressure (EtCO2), tidal volume, respiratory rate, barometric pressure (pB = 760mm Hg), partial pressure of water vapor (PH2O = 13 mm Hg), and patient weight (kg)

Time frame:
Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
Reported as:
Mean · mmHg
Carbon Dioxide Elimination (mmHg)
mmHgAirSeal SystemStandard Endopath
Baseline3.15 ± 0.673.28 ± 0.64
60 minutes3.24 ± 0.743.28 ± 0.6
End of procedure3.04 ± 1.353.11 ± 0.65
Statistical analysis
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.42 (Comparison at baseline)
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.75 (Comparison at 60 minutes)
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.99 (Comparison at end of procedure)
SecondaryIntraoperative Arterial Blood Gas Oxygen (mmHg).

The amount of dissolved oxygen (PaO2) in arterial blood (mmHg).

Time frame:
Baseline, 60 minutes, and end of procedure, an average of 156 minutes
Reported as:
Mean · mmHg
Intraoperative Arterial Blood Gas Oxygen (mmHg).
mmHgAirSeal SystemStandard Endopath
Baseline361.9 ± 79.3364.3 ± 81.9
60 minutes283.9 ± 115.4294 ± 105.0
End of procedure286.5 ± 99.1290.2 ± 99.4
Statistical analysis
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.88 (Comparison at baseline)
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.65 (Comparison at 60 minutes)
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.86 (Comparison at end of procedure)
SecondaryNumber of Ventilator Interventions

The number of times the anesthesiologist had to adjust ventilator settings

Time frame:
Through end of procedure, an average of 156 minutes
Reported as:
Mean · Count of interventions
Number of Ventilator Interventions
Count of interventionsAirSeal SystemStandard Endopath
Number of Ventilator Interventions0.69 ± 1.10.66 ± 0.9
Statistical analysis
  • AirSeal System vs Standard Endopath · Zero-inflated Poisson regression · p = 0.41
SecondaryProcedure Time (Minutes)

The duration of the procedure

Time frame:
Through end of procedure, an average of 156 minutes
Reported as:
Mean · Minutes
Procedure Time (Minutes)
MinutesAirSeal SystemStandard Endopath
Procedure Time (Minutes)158.6 ± 22.4153.0 ± 19.9
Statistical analysis
  • AirSeal System vs Standard Endopath · t-test, 2 sided · p = 0.09
SecondarySmoke Evacuation Quality

Smoke evacuation quality throughout the procedure was assessed by the surgeon as below average, average, or above average

Time frame:
Through end of procedure, an average of 156 minutes
Reported as:
Count of participants · Participants
Smoke Evacuation Quality
ParticipantsAirSeal SystemStandard Endopath
Below Average416
Average2518
Above Average2014
Statistical analysis
  • AirSeal System vs Standard Endopath · Chi-squared · p = <0.001

Adverse events

Collected over Through hospital discharge, an average of 8.4 hours. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AirSeal System0/50 (0%)0/50 (0%)1/50 (2%)
Standard Endopath0/50 (0%)0/50 (0%)3/50 (6%)
Most frequent other events
Most frequent other events
EventAirSeal SystemStandard Endopath
NauseaGastrointestinal disorders1/503/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)AirSeal SystemStandard EndopathTotal
Mean61.0 ± 5.662.0 ± 6.761.5 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)AirSeal SystemStandard EndopathTotal
FemaleNANANA
Male5050100
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AirSeal SystemStandard EndopathTotal
Race/Ethnicity — Caucasian504292
Race/Ethnicity — African American077
Race/Ethnicity — Other011
Region of Enrollment
Region of Enrollment(participants)AirSeal SystemStandard EndopathTotal
United States5050100
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)AirSeal SystemStandard EndopathTotal
Mean29.1 ± 4.328.3 ± 3.328.7 ± 3.8
Preoperative hemoglobin
Preoperative hemoglobin(g/dL)AirSeal SystemStandard EndopathTotal
Mean15.1 ± 1.014.7 ± 1.014.8 ± 1.0
Preoperative creatinine
Preoperative creatinine(mg/dL)AirSeal SystemStandard EndopathTotal
Mean0.89 ± 0.10.96 ± 0.20.92 ± 0.1
08

Study locations

1 site
  • Dublin Methodist Hospital
    Columbus, Ohio 43016, United States
09

References and documents

Publications

  • Abaza R, Martinez O, Murphy C. Randomized Controlled Comparison of Valveless Trocar (AirSeal) vs Standard Insufflator with Ultralow Pneuomoperitoneum During Robotic Prostatectomy. J Endourol. 2021 Jul;35(7):1020-1024. doi: 10.1089/end.2020.1025. Epub 2021 Jan 21. PubMed 33349135 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of May 2018 and a completion of Jul 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2021, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2014
First posted
Apr 15, 2014
Start
Aug 2016
Primary completionActual
May 3, 2018
CompletionActual
Jul 15, 2019
Results first posted
Nov 26, 2021
Last update
Nov 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02114164
Lead sponsor
OhioHealth
Collaborators
SurgiQuest, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Aug 2016
Primary completion
May 3, 2018
Completion
Jul 15, 2019
Results posted
Nov 26, 2021
Last update
Nov 26, 2021

Study contacts

Ronney Abaza, MD,FACS
principal investigator · OhioHealth

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion